Neurogene
Neurogene Inc is an American clinical-stage genetic medicine biotechnology company specializing in the development of life-changing genetic medicines for rare, severe neurological diseases, prominently featuring proprietary adeno-associated virus (AAV) vector technologies designed to address complex neurological disorders such as Rett syndrome and Batten disease. The company designs, tests, and manufactures advanced gene therapies intended to deliver functional genes to the central nervous system. Its core business operations encompass genetic medicine research, viral vector manufacturing, preclinical and clinical trial execution, and intellectual property licensing. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings and strategic biopharmaceutical partnerships. Neurogene holds a pioneering market position in genetic therapies for severe neurological conditions. The company is headquartered in Boston, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Neurogene.
- Legal name
- Neurogene Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Neurogene
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.55 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.03 % (full portfolio disclosed, October 2026)